Taysha Gene Therapies, Inc. 8-K

What Happened

• Taysha Gene Therapies, Inc. announced the results of its 2026 annual meeting held on June 1, 2026. Of 287,341,999 shares outstanding, 243,857,812 (84.86%) were present or represented by proxy.
• Two director nominees, Sean P. Nolan and Laura Sepp-Lorenzino, Ph.D., were elected to serve until the 2029 annual meeting. Deloitte & Touche LLP was ratified as the independent registered public accounting firm for fiscal 2026. Stockholders approved, on a non‑binding basis, the compensation of the company’s named executive officers and indicated a preferred annual frequency for future advisory votes on executive pay; the Board will solicit the advisory vote every year.

Key Details

• Shares outstanding (record date): 287,341,999; shares present/represented: 243,857,812 (84.86%).
• Director election votes: Sean P. Nolan — 169,142,295 for / 35,742,331 withheld; Laura Sepp‑Lorenzino — 150,094,517 for / 54,790,109 withheld. Broker non‑votes: 38,973,186.
• Auditor ratification: Deloitte & Touche LLP — 243,814,085 for / 25,551 against / 18,176 abstained (0 broker non‑votes).
• Executive compensation (non‑binding): 168,142,551 for / 36,396,784 against / 345,291 abstained. Preferred frequency vote: One year — 203,825,717; Two years — 360,924; Three years — 630,378; Abstain — 67,607. Broker non‑votes on these matters: 38,973,186.

Why It Matters

• These outcomes affect governance and oversight: the elected directors will serve through 2029 and the auditor ratification maintains continuity of external financial review. The non‑binding executive pay approval and strong preference for annual advisory votes signal stockholder support for the company’s executive compensation approach and mean the Board will hold say‑on‑pay votes each year. Investors should note the level of broker non‑votes on certain items, which can reflect uninstructed institutional holdings but did not impact the auditor ratification vote.